首页> 外文OA文献 >Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
【2h】

Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

机译:评估:肉毒杆菌神经毒素在自主神经系统疾病和疼痛的治疗中(基于证据的综述):美国神经科学院治疗与技术评估小组委员会的报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

OBJECTIVE: To perform an evidence-based review of the safety and efficacy of botulinum neurotoxin (BoNT) in the treatment of autonomic and urologic disorders and low back and head pain. METHODS: A literature search was performed including MEDLINE and Current Contents for therapeutic articles relevant to BoNT and the selected indications. Authors reviewed, abstracted, and classified articles based on the quality of the study (Class I-IV). Conclusions and recommendations were developed based on the highest level of evidence and put into current clinical context. RESULTS: The highest quality literature available for the respective indications was as follows: axillary hyperhidrosis (two Class I studies); palmar hyperhidrosis (two Class II studies); drooling (four Class II studies); gustatory sweating (five Class III studies); neurogenic detrusor overactivity (two Class I studies); sphincter detrusor dyssynergia in spinal cord injury (two Class II studies); chronic low back pain (one Class II study); episodic migraine (two Class I and two Class II studies); chronic daily headache (four Class II studies); and chronic tension-type headache (two Class I studies). RECOMMENDATIONS: Botulinum neurotoxin (BoNT) should be offered as a treatment option for the treatment of axillary hyperhidrosis and detrusor overactivity (Level A), should be considered for palmar hyperhidrosis, drooling, and detrusor sphincter dyssynergia after spinal cord injury (Level B), and may be considered for gustatory sweating and low back pain (Level C). BoNT is probably ineffective in episodic migraine and chronic tension-type headache (Level B). There is presently no consistent or strong evidence to permit drawing conclusions on the efficacy of BoNT in chronic daily headache (mainly transformed migraine) (Level U). While clinicians' practice may suggest stronger recommendations in some of these indications, evidence-based conclusions are limited by the availability of data.
机译:目的:对肉毒杆菌神经毒素(BoNT)在治疗植物神经和泌尿系统疾病以及下背部和头部疼痛中的安全性和有效性进行循证审查。方法:进行了文献检索,包括MEDLINE和当前目录中与BoNT相关的治疗性文章和所选适应症。作者根据研究质量(I-IV级)对文章进行了摘要,摘要和分类。结论和建议是根据最高水平的证据提出的,并已纳入当前的临床背景。结果:关于各种适应症的最高质量文献如下:腋窝多汗症(两项I类研究);手掌多汗症(两项II类研究);流口水(四项II类研究);味觉出汗(5项III类研究);神经源性逼尿肌过度活动(两项I类研究);脊髓损伤中括约肌逼尿肌功能不全(两项II类研究);慢性腰背痛(一项II类研究);发作性偏头痛(两项I级和两项II级研究);慢性每日头痛(两项II类研究);和慢性紧张型头痛(两项I类研究)。建议:肉毒杆菌神经毒素(BoNT)应作为腋窝多汗症和逼尿肌过度活动的治疗选择(A级),应考虑脊髓损伤后手掌多汗,流口水和逼尿肌括约肌功能障碍(B级),并可能考虑用于味觉出汗和腰痛(C级)。 BoNT在发作性偏头痛和慢性紧张性头痛中可能无效(B级)。目前尚无一致或有力的证据可以得出关于BoNT在慢性每日头痛(主要是转化性偏头痛)中功效的结论(U级)。尽管临床医生的实践可能会在某些适应症中提出更强有力的建议,但基于证据的结论受到数据可用性的限制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号